Phaseline

Companies › SynerGene Therapeutics

SynerGene Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SGT-53
p53 gene therapy delivered by lipid nanoparticles
TP53Phase 2Metastatic Pancreatic CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02340117SGT-53Phase 2Metastatic Pancreatic CancerOncologyDec 2026

Targets

TP53 (1)

Companies with the same targets

PMV Pharmaceuticals Kartos Therapeutics Precigen OSE Immunotherapeutics Changchun GeneScience Pharmaceutical Nutshell Therapeutics (Shanghai) Jacobio Pharmaceuticals Clasp Therapeutics

Companies built like this

iOnctura Toray Industries Lyvgen Biopharma Holdings Imvax Klus Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.